Royalty Pharma's total assets for Q4 2025 were $19.62B, an increase of 1.41% from the previous quarter. RPRX total liabilities were $9.91B for the fiscal quarter, a 1.85% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.